Skip to nav Skip to content

Clinical Trial Search

306 Clinical Trials Found

Clinical Trial 20831

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 21024

A Phase IIa Study of Dendritic Cell Vaccines against HER2/HER3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Disease Site: Brain and Nervous System
PI: Forsyth, Peter

Clinical Trial 20871

A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Disease Site: Unknown Sites
PI: Nishihori, Taiga

Clinical Trial 20963

A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Disease Site: Myeloid and Monocytic Leukemia
PI: Kuykendall, Andrew

Clinical Trial 21143

Disease Site: Other
PI: Sokol, Lubomir

Clinical Trial 21623

A Phase 1/2 Study of bbT369, a Dual Targeting CAR T cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B cell Non-Hodgkin s Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
PI: Locke, Frederick

Clinical Trial 21415

Disease Site: Other Hematopoietic
PI: Kuykendall, Andrew

Clinical Trial 21626

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 21707

A Proof of Concept Study of TBio-4101 (an Autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) Using Short-Term Cultured, Selected Autologous TIL following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Solid Tumors (Phase 1)
Disease Site: Colon, Melanoma, skin, Rectum
PI: Sarnaik, Amod

Clinical Trial 22095

Disease Site: Myeloid and Monocytic Leukemia
PI: Kuykendall, Andrew

Clinical Trial 22096

A Phase 1 Open-Label, Dose-Escalation, Safety, and Tolerability Study of JSP191 as a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)
Disease Site: Other Hematopoietic
PI: Lancet, Jeffrey

Clinical Trial 22100

Disease Site: Multiple Myeloma
PI: Grajales-Cruz, Ariel